Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

<p>Molecular landscape of HGSOC. <sup>1</sup>Mutation in non-<i>BRCA1</i>/<i>2</i> HRR genes: 3 <i>BRIP1</i>, 2 <i>CHEK2</i>, 1 <i>RAD51C</i>, 1 <i>PALB2</i>, 1 concurrent <i>BAP1</i> and <i>N...

Повний опис

Збережено в:

Бібліографічні деталі
Автор:	Robert L. Hollis (15034814) (author)
Інші автори:	Alison M. Meynert (14956260) (author), Caroline O. Michie (15043392) (author), Tzyvia Rye (4733277) (author), Michael Churchman (15034811) (author), Amelia Hallas-Potts (15043395) (author), Ian Croy (15034823) (author), W. Glenn McCluggage (8775452) (author), Alistair R.W. Williams (15043398) (author), Clare Bartos (15034820) (author), Yasushi Iida (4097272) (author), Aikou Okamoto (14957624) (author), Brian Dougherty (108958) (author), J. Carl Barrett (11900099) (author), Ruth March (73809) (author), Athena Matakidou (15034847) (author), Patricia Roxburgh (14961464) (author), Colin A. Semple (15034853) (author), D. Paul Harkin (14873531) (author), Richard Kennedy (248483) (author), C. Simon Herrington (15034817) (author), Charlie Gourley (15034850) (author)
Опубліковано:	2025
Предмети:	Cancer Cancer Biology Tumor Biology Therapeutic Research and Development Clinical Research and Trials Gynecological Cancers Ovarian cancer Oncogenes & Tumor Suppressors BRCA family Precision Medicine Translational Research Tumor Microenvironment Immune cells and the microenvironment
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
за авторством: Robert L. Hollis (15034814)
Опубліковано: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
за авторством: Robert L. Hollis (15034814)
Опубліковано: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
за авторством: Robert L. Hollis (15034814)
Опубліковано: (2025)

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
за авторством: Robert L. Hollis (15034814)
Опубліковано: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
за авторством: Robert L. Hollis (15034814)
Опубліковано: (2025)

Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
за авторством: Jennifer L. Cotton (17315204)
Опубліковано: (2025)

Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
за авторством: Jennifer L. Cotton (17315204)
Опубліковано: (2025)

Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
за авторством: Jennifer L. Cotton (17315204)
Опубліковано: (2025)

Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
за авторством: Jennifer L. Cotton (17315204)
Опубліковано: (2025)

Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
за авторством: Jennifer L. Cotton (17315204)
Опубліковано: (2025)

Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
за авторством: Jennifer L. Cotton (17315204)
Опубліковано: (2025)

Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
за авторством: Jennifer L. Cotton (17315204)
Опубліковано: (2025)

Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
за авторством: Jennifer L. Cotton (17315204)
Опубліковано: (2025)

Supplemental Tables 1 - 12 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
за авторством: Jennifer L. Cotton (17315204)
Опубліковано: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
за авторством: Sanna Pikkusaari (15055802)
Опубліковано: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
за авторством: Sanna Pikkusaari (15055802)
Опубліковано: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
за авторством: Kankan Cao (16437263)
Опубліковано: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
за авторством: Arun Kanakkanthara (14937731)
Опубліковано: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
за авторством: Arun Kanakkanthara (14937731)
Опубліковано: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S7 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Supplementary Video from Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma
за авторством: Laura Privitera (16015972)
Опубліковано: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
за авторством: Alexander N. Shoushtari (15023909)
Опубліковано: (2025)

Supplementary Figure S1 from G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer
за авторством: Anita L. Ray (15313398)
Опубліковано: (2025)

Supplementary Figure S2 from G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer
за авторством: Anita L. Ray (15313398)
Опубліковано: (2025)

Tables 2 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
за авторством: Simon P. Beyaert (17141915)
Опубліковано: (2025)

Tables 3 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
за авторством: Simon P. Beyaert (17141915)
Опубліковано: (2025)

Supplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
за авторством: Robin M. Hallett (15037427)
Опубліковано: (2025)

Supplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
за авторством: Robin M. Hallett (15037427)
Опубліковано: (2025)

Supplementary Figure 1 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
за авторством: Patrizia Mondello (15045002)
Опубліковано: (2025)

Supplementary Figure 2 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
за авторством: Patrizia Mondello (15045002)
Опубліковано: (2025)

Supplementary Figure 3 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
за авторством: Patrizia Mondello (15045002)
Опубліковано: (2025)

Supplementary Figure 4 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
за авторством: Patrizia Mondello (15045002)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_qvp5fq9388ummc3uao2phc3lc9